Coya deems dementia drug R&D plan 'premature,' switches focus

Coya Therapeutics’ plan to treat frontotemporal dementia (FTD) by boosting the function of regulatory T cells (Tregs) is unraveling. Months after putting FTD at the heart of its IPO pitch, the biotech has decided it would be “premature” to continue to study its low-dose formulation of IL-2 in the indication.